Effects of erythropoietin on ICAM‐1 and PECAM‐1 expressions on human umbilical vein endothelial cells subjected to oxidative stress

Abstract

The protective effect of erythropoietin (Epo) is based on its ability to reduce oxidation and to stabilize the cells. The aim of the study was to evaluate the influence of Epo on malonyl dialdehyde (MDA), intercellular adhesion molecule-1 (ICAM-1) (CD54) and platelet-endothelial cell adhesion molecule-1 (PECAM-1) (CD31) levels on human umbilical vein endothelial cells (HUVECs) stimulated by tumour necrosis factor-α (TNF-α). HUVECs were incubated with Epo (10-40 IU ml⁻¹) or TNF-α (10-40 ng ml⁻¹) alone or preincubated with Epo (20 IU ml⁻¹) and subsequently stimulated with TNF-α (10-40 ng ml⁻¹). MDA concentrations were measured using the high-performance liquid chromatography, whereas ICAM-1 and PECAM-1 expressions were evaluated by flow cytometry. Incubation with Epo resulted in a decrease in MDA and the increased expressions of ICAM-1 and PECAM-1. Exposure to TNF-α reflected an increase in MDA, ICAM-1 and PECAM-1 levels. These changes were inhibited by preincubation with Epo. The cytoprotective activity proven in this study points to new applications and therapeutic possibilities for Epo.

Erythropoietin: New Directions for the Nervous System

“…Oxidative stress impacts every system of the body and can lead to cell death in the vasculature system [73,99–103], the immune system [104–106], the cardiac system [84,107–110], and the brain [111–119]. Oxidative stress also may be a contributing factor to the complications of diabetes mellitus [109,120–125] and cerebral cognitive loss [126,127].…”

“…EPO can block the generation of ROS [27], may prevent oxidative stress at high altitudes [144], and is cytoprotective against oxidative stress that is stimulated by tumor necrosis factor-α (TNF-α) [73]. EPO also can limit oxidative stress injury during cisplatinum administration [42,145] and in models of Parkinson’s disease [57].…”

“…EPO also can limit oxidative stress injury during cisplatinum administration [42,145] and in models of Parkinson’s disease [57]. EPO can preserve cellular integrity in neurons [35,55,82,146,147], vascular cells [25,68–73,76,148], and inflammatory cells of the nervous system [37,77–79,149] during oxidant stress mediated injury.…”

Effect of erythropoietin on bone marrow mononuclear cells

“…В работе авторов показано, что костномозговые мезенхимальные стволовые клетки мышей C57BL/6 от 3-го пассажа несут на своей мембране CD29 [14]. Показано, что эритропоэтин индуцирует снижение уровней малонового альдегида и повышение экспрессии CD54 и CD31 в клетках, полученных из эндотелия вен пупочного канатика человека (HUVEC) [10]. Дарбэпоэтин альфа (эритропоэз-стимулирующий агент) у больных с хронической почечной недостаточностью повышает количество эндотелиальных прогениторных клеток, несущих на своей поверхности CD146 после 4 недель терапии [17].…”

Regeneration in the nervous system with erythropoietin

“…In relation to blocking the detrimental effects of oxidative stress and ROS, EPO protects endothelial cells (144, 194, 199, 203, 204, 214, 220, 221, 316, 368, 371–376), neurons (26, 210, 237, 345, 362, 377–382), astrocytes (377, 383–385), and microglia (166, 186, 196, 227, 368, 381). During oxidative stress, EPO also preserves neurogenesis (336, 386), stem cell development (126, 220, 237, 312, 372, 387), and promotes erythroid progenitor cell development with the modulation of FoxO3a activity (29, 169, 237, 307).…”